Research programme: dengue fever therapies - NanoViricides/Walter Reed Army Institute of Research

Drug Profile

Research programme: dengue fever therapies - NanoViricides/Walter Reed Army Institute of Research

Alternative Names: DengiCide; DengueCide

Latest Information Update: 12 Nov 2013

Price : $50

At a glance

  • Originator NanoViricides; Walter Reed Army Institute of Research
  • Developer NanoViricides; University of California at Berkeley; Walter Reed Army Institute of Research
  • Class Polymers
  • Mechanism of Action Virus internalisation inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Dengue
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Dengue

Most Recent Events

  • 11 Nov 2013 DengueCide™ receives Orphan Drug status for Dengue in European Union
  • 07 Aug 2013 DengueCidereceives Orphan Drug status for Dengue in USA
  • 02 Apr 2013 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top